Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Kostos, Louise Kathleen
Lai, William Yu Ching
Lambroglou, Peter
Medhurst, Elizabeth
Buteau, James Patrick
Sandhu, Shahneen
Tran, Ben
Spain, Lavinia Anne
Conduit, Ciara
Wallace, Roslyn
Alipour, Ramin
Akhurst, Timothy J.
Kong, Grace
Cardin, Anthony
Saghebi, Javad
Kumar, Aravind Ravi
Hofman, Michael S.
Azad, Arun
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Mol Imaging & Therapeut Nucl Med, Canc Imaging, Prostate Canc Theranost & Imaging Ctr Excellence, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77
引用
收藏
页数：1
相关论文
共 50 条
  • [41] 177Lu-PSMA-617 Treatment of Metastatic Castration-Resistant Prostate Cancer: Efficacy and Survival
    Demirci, E.
    Akyel, R.
    Sahin, O.
    Ocak, M.
    Aygun, A.
    Pehlivanoglu, H.
    Karayel, E.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S202 - S203
  • [42] Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177-PSMA-617 (Lu) based on line of therapy.
    Sayegh, Nicolas
    Jo, Yeonjung
    Ozay, Zeynep Irem
    Chehade, Chadi Hage
    Gebrael, Georges
    Ostrowski, Micah
    Campbell, Patrick
    Tripathi, Nishita
    Hu, Siqi
    Chigarira, Beverly
    Anderson, Ethan
    Ji, Richard
    Fortuna, Gliceida Galarza
    Thomas, Vinay Mathew
    Li, Haoran
    Gupta, Sumati
    Maughan, Benjamin L.
    Agarwal, Neeraj
    Swami, Umang
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [43] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [44] 177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer
    Derlin, Thorsten
    Widjaja, Liam
    Werner, Rudolf A.
    Bengel, Frank M.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 54 - 58
  • [45] Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu] Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)
    Fettke, Heidi
    Kostos, Louise
    Buteau, James
    Steen, Jason A.
    Medhurst, Elizabeth
    Haskali, Mo B.
    Murphy, Declan
    Docanto, Maria
    Bukczynska, Patricia
    Ng, Nicole
    Sandhu, Shahneen
    Foroughi, Siavash
    Furic, Luc
    Nguyen-Dumont, Tu
    Hofman, Michael S.
    Azad, Arun A.
    CANCER RESEARCH, 2023, 83 (07)
  • [46] Association of tumor genetics with outcomes in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617.
    Panian, Justine
    Henderson, Nicholas
    Barata, Pedro C.
    Bilen, Mehmet Asim
    Graham, Laura
    Heath, Elisabeth I.
    Herchenhorn, Daniel
    Hwang, Clara
    Kilari, Deepak
    Koshkin, Vadim S.
    Nauseef, Jones T.
    Sokolova, Alexandra
    Zakharia, Yousef
    Schweizer, Michael Thomas
    Dorff, Tanya B.
    Armstrong, Andrew J.
    Alva, Ajjai Shivaram
    Mckay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
    Justin Ferdinandus
    John Violet
    Shahneen Sandhu
    Rodney J. Hicks
    Aravind S. Ravi Kumar
    Amir Iravani
    Grace Kong
    Tim Akhurst
    Sue Ping Thang
    Declan G. Murphy
    Scott Williams
    Michael S. Hofman
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2322 - 2327
  • [48] Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
    Ferdinandus, Justin
    Violet, John
    Sandhu, Shahneen
    Hicks, Rodney J.
    Ravi Kumar, Aravind S.
    Iravani, Amir
    Kong, Grace
    Akhurst, Tim
    Thang, Sue Ping
    Murphy, Declan G.
    Williams, Scott
    Hofman, Michael S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (10) : 2322 - 2327
  • [49] Treatment efficacy and safety of 177Lu-PSMA Radioligand Therapy in Octogenarians with metastatic castration-resistant prostate cancer
    Langbein, T.
    Retz, M.
    D'Alessandria, C.
    Grigorascu, S.
    Hansen, K.
    Wester, H.
    Gschwend, J.
    Weber, W.
    Eiber, M.
    Tauber, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S132 - S133
  • [50] Activity of lutetium-177 PSMA (Lu-PSMA) and determinants of outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with cabazitaxel: The PACAP study.
    Flippot, Ronan
    Telli, Tugce
    Velev, Maud
    Flechon, Aude
    Turpin, Lea
    Bergman, Andre M.
    Turco, Fabio
    Fendler, Wolfgang Peter
    Giraudet, Anne Laure
    Montravers, Francoise
    Vogel, Wouter V.
    Gillessen, Silke
    Berardi, Simona
    Herrmann, Ken
    Kryza, David
    Paone, Gaetano
    Garcia, Camilo
    Foulon, Stephanie
    Pages, Arnaud
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345